MRNAMRNA
US • —
$70.03
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
-30.0% YoY
Gross Margin
35.0%
Health Score
5/10
D/E Ratio
0.07
Confidence
LOW
Business Snapshot
Moderna operates as a biotechnology company focused on messenger RNA (mRNA) therapeutics and vaccines. Its primary revenue-generating product has been the Spikevax COVID-19 vaccine, though the company is also developing a pipeline of mRNA-based candidates targeting respiratory viruses, oncology, and rare diseases. The company operates in the highly competitive vaccine and therapeutic market, where it has established itself as a pioneer in mRNA technology but now faces declining demand for its core COVID product. With a market cap and TTM revenue not available in the analyzed data, the company's current financial scale cannot be precisely determined from this dataset. A defining characteristic is its proprietary mRNA platform, which provides a technological foundation for a broad pipeline but also concentrates revenue risk heavily in a single product category.
Financial Health
Gross margin stands at 35.0%, while net margin of -143.6% — note this figure may be distorted due to a one-time item or data anomaly, making profitability assessment unreliable from this metric. The balance sheet shows a debt/equity ratio of just 0.07x and a current ratio of 3.29x, indicating a very conservative capital structure with minimal leverage and strong short-term liquidity...
Risk Assessment
- REVENUE DECELERATION — Revenue declined 30.0% year-over-year, a sharp reversal that signals the core COVID vaccine franchise is contracting rapidly.
- EARNINGS QUALITY — Despite 4 of 4 recent earnings beats, negative net margin and -36.7% ROE indicate underlying profitability is structurally weak.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- VALUATION — Price-to-sales of 12.39x is a premium multiple for a company with declining revenue, implying elevated expectations for a growth turnaround.
- FCF / CASH BURN — Free cash flow data is not available, but the combination of -36.7% ROE and negative net margin suggests the company is generating insufficient returns to sustain its valuation without continued access to capital....
Gross margin stands at 35.0%, while net margin of -143.6% — note this figure may be distorted due to a one-time item or data anomaly, making profitability assessment unreliable from this metric. The balance sheet shows a debt/equity ratio of just 0.07x and a current ratio of 3.29x, indicating a very conservative capital structure with minimal leverage and strong short-term liquidity. Return on equity is deeply negative at -36.7%, reflecting that the company is generating substantial losses relative to shareholder equity. Free cash flow figures are not available in this dataset, preventing assessment of whether the company is funding operations through cash generation or burning through reserves. Overall financial health is characterised by a fortress-like balance sheet with low debt and ample liquidity, but profitability remains elusive, limiting the company's ability to reinvest aggressively or pay dividends without relying on existing cash reserves.
- REVENUE DECELERATION — Revenue declined 30.0% year-over-year, a sharp reversal that signals the core COVID vaccine franchise is contracting rapidly. - EARNINGS QUALITY — Despite 4 of 4 recent earnings beats, negative net margin and -36.7% ROE indicate underlying profitability is structurally weak. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - VALUATION — Price-to-sales of 12.39x is a premium multiple for a company with declining revenue, implying elevated expectations for a growth turnaround. - FCF / CASH BURN — Free cash flow data is not available, but the combination of -36.7% ROE and negative net margin suggests the company is generating insufficient returns to sustain its valuation without continued access to capital.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives